Coulter Partners successfully completed a search assignment for Altimmune Inc. (Nasdaq: ALT), and is pleased to announce the placement of biopharmaceutical industry executives Teri Lawver and Jerry Durso to its Board of Directors.

Altimmune is a late clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity, MASH and other indications.

Commenting on the search work with Coulter Partners, Vipin K. Garg, Ph.D., President and Chief Executive Officer of Altimmune, said:

“Coulter Partners’ deep life sciences expertise and proactive approach helped us secure top-tier talent. We value our partnership and look forward to continuing our collaboration.”

About Coulter Partners

We are executive search and leadership development specialists working to build a better future. As advisors and consultants to companies at the cutting edge of Health, Science, and Technology, we are united by our mission to build teams that change the world. Operating uniquely as one global team, we have honed our expertise, platform, and data for over two decades, working across three continents, and in 40 countries. Applying what we learn through our work with boards, leadership teams, and investors in the world’s most innovative companies, we bring together and develop the right people at the right time to propel them to achieve their worthwhile goals.

www.coulterpartners.com